Propria develops engineered heart tissues (hEHTs) that closely mimic adult human myocardium, enabling precise in vitro cardiac contractility testing for disease models and therapeutics. This technology provides reliable and predictive data, enhancing the drug discovery process by allowing scientists to evaluate compounds with greater accuracy than traditional rodent models.
Funding
$121K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for testing cardiac contractility rely heavily on animal models, which often fail to accurately predict human physiological responses to new therapeutics. This discrepancy leads to costly late-stage drug failures and limits the development of effective treatments for heart diseases.
Solution
Propria offers in vitro cardiac contractility testing services using human engineered heart tissues (hEHTs) that closely mimic adult human myocardium. Their hEHTs enable comprehensive contractile profiling, providing more realistic and predictive data compared to traditional rodent models. Propria's system produces detailed datasets, allowing scientists to evaluate the full contractile profile of human tissues. The thin, ribbon-like structure of Propria's hEHTs ensures adequate oxygen diffusion, enabling longer-term contractility testing. Propria also provides data analysis and interpretation by experienced cardiac muscle physiologists.
Target Audience
Propria's primary customers are scientists and pharmaceutical companies involved in drug discovery and development for cardiac diseases.
Features
- Human engineered heart tissues (hEHTs) with cellular composition closely resembling adult human myocardium
- Isometric twitch kinetics that mimic human data more reliably than rodent models
- Thin, ribbon-like tissue structure within the diffusion limit of oxygen for longer-term contractility testing
- Comprehensive contractile profiling services for disease models and new therapeutics
- Specialized instrumentation for robust and replicable datasets
- Built-in quality control metrics of tissue performance
- Data analysis and interpretation by PhD-level cardiac muscle physiologists